Bright Minds Biosciences

-Biotechnology

Focus: Bright Minds Biosciences is a psychedelics-focused biotechnology company developing novel psychiatric therapeutics, currently in early-stage clinical development with a single lead compound in Phase 1/2 evaluation.

Psychiatry

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Bright Minds Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Bright Minds Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BMB-101

Healthy

Phase 1

Clinical Trials (1)

NCT05397041A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers

Phase 1

Help build intelligence for Bright Minds Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work in high-growth psychedelics sector with significant unmet need in psychiatry and neurological disorders
Ground-floor position at early-stage biotech with potential for meaningful equity upside as company progresses through clinical development
Diverse pipeline addressing multiple psychiatric and neurological indications (absence epilepsy, Prader-Willi syndrome) beyond psychiatry

Watch Out For

Company is pre-revenue with no approved products and limited public financial transparency or disclosed funding
Very early-stage pipeline with only 3 active trials total and no Phase 3 programs; significant regulatory and clinical risk ahead
Currently zero open job postings, suggesting minimal active hiring or potential organizational contraction

Generated by Claude from Bright Minds Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BMB-101

Prader-Willi Syndrome

Phase 2

Clinical Trials (1)

NCT07266324A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

Phase 2

BMB-101

Absence Epilepsy

Phase 2

Clinical Trials (1)

NCT06401538BMB-101 in Absence Epilepsy and DEE

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline